课题基金 / 基金详情

PHARMACOLOGY OF OPTIMARK IN PATIENTS WITH CNS OR LIVER PATHOLOGY

PHARMACOLOGY OF OPTIMARK IN PATIENTS WITH CNS OR LIVER PATHOLOGY
OPTIMARK 在中枢神经系统或肝脏病变患者中的药理学
批准号：
6121111
负责人：
BRUCE J BARRON
金额：
$1.51万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/6121111
关键词：
chelating agents clinical research clinical trial phase I contrast media dosage drug adverse effect drug screening /evaluation gadolinium human subject liver disorder magnetic resonance imaging neuropathology pharmacology

项目摘要

项目成果

BRUCE J BARRON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary aim of this Phase I study is to evaluate the pharmacological dose-related effects of a newly developed contrast agent for use with MRI. Agents currently being used are available in doses of 0.1 to 0.3 mmol/kg. This new agent is a non-ionic, extracellular, linear gadolinium based chelate that will be tested in doses of 0.1, 0.3, and 0.5 mmol/kg. Subjects will be patients with known brain, spine, and/or liver disease, and were chosen to be representative of the type of patient for which contrast MRI is currently being used. This study was completed in September, 1997.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHARMACOLOGY OF OPTIMARK IN PATIENTS WITH CNS OR LIVER PATHOLOGY
PHARMACOLOGY OF OPTIMARK IN PATIENTS WITH CNS OR LIVER PATHOLOGY
海外基金